Abstract
Once-weekly semaglutide 2.4 mg, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is approved for weight management in adults with obesity, or overweight and ≥1 weight-related condition. However, limited real-world evidence on clinical outcomes of these patients exists. The aim of this real-world study is to understand the impact of semaglutide 2.4 mg on weight loss in patients in the US.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.